Shares of biotech company Moderna, which focuses on drug discovery and drug development based on messenger RNA, dropped nearly 20% on its opening debut in the market. Despite the drop, the company raised $604.3 million for an initial public offering, making it the biggest in biotech history. According to CNBC’s Jim Cramer, “There’s more to … Continue reading “Jim Cramer Said This of Moderna’s IPO Tumble”